MedTrace Logo

Optimal Blood Pressure Treatment Thresholds Postpartum

NCT06069102 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2026-01-08

No results posted yet for this study

Summary

The objective of this research project is to conduct a single-site pilot trial within our institution's clinical remote blood pressures (BP) management program to assess the feasibility and effect of tight blood pressure control versus usual care in the immediate postpartum period after a hypertensive disorder of pregnancy (HDP).

The investigators' central hypothesis is that tight blood pressure control will be feasible and acceptable to postpartum individuals and will result in lower BP at six months postpartum and a reduction in postpartum hospital readmissions. Subjects will undergo 3 study visits (1 in-person and 2 remote) involving BP measurements, blood draws, and/or questionnaires. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.

Conditions

  • Hypertensive Disorder of Pregnancy
  • Pre-Eclampsia
  • Hypertension
  • Eclampsia
  • Gestational Hypertension
  • Cardiovascular Diseases
  • Toxemia
  • Pregnancy Complications
  • Vascular Diseases
  • Hypertension, Pregnancy Induced
  • Hypertension;Pre-Eclamptic

Interventions

DRUG

Usual care

The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.

DRUG

Tight blood pressure control

The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.

Sponsors & Collaborators

  • Alisse Hauspurg

    lead OTHER

Principal Investigators

  • Alisse K Hauspurg, MD · UPMC Magee Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2025-05-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06069102 on ClinicalTrials.gov